Literature DB >> 20980914

Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment.

Katharina Grabmeier-Pfistershammer1, Peter Steinberger, Armin Rieger, Judith Leitner, Norbert Kohrgruber.   

Abstract

PD-1 expression on T cells correlates with T-cell exhaustion and disease progression in HIV-infected patients. Previous studies have shown that combinational antiretroviral therapy induced viral suppression results in immune restoration and reduced PD-1 expression. However, a significant number of patients fail to restore CD4 T cells despite suppression of HIV replication below limit of quantification. In this study, we have analyzed PD-1 expression on CD4 and CD8 T cells in patients with poor immune reconstitution despite successful highly active antiretroviral therapy. We found that T cells of such patients express significantly higher levels of PD-1 than patients who had normal recovery of CD4 cells after treatment. In contrast, failing immune reconstitution was not associated with the expression of activation markers, indicating that PD-1 is a unique marker for failing immune reconstitution despite viral suppression. Furthermore, we show that T cells from patients with poor immune recovery differ from T cells of elderly in respect of their marker profile. PD-1 expression negatively correlated with individual CD4 cell counts, and PD-1 expressing T cells were more prone to programmed death ligand-mediated inhibition of T-cell proliferation, indicating that PD-1-mediated T-cell suppression may have a role in impaired immune reconstitution in HIV patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20980914     DOI: 10.1097/QAI.0b013e3181fbab9f

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  39 in total

Review 1.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Authors:  Sergei Spitsin; Nancy B Tustin; Eric Riedel; Richard Tustin; Jennifer B Murray; Lauren M Peck; Mohammad Khan; Joseph Quinn; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

3.  Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection.

Authors:  Carey L Shive; Brian Clagett; Marie R McCausland; Joseph C Mudd; Nicholas T Funderburg; Michael L Freeman; Souheil-Antoine Younes; Brian M Ferrari; Benigno Rodriguez; Grace A McComsey; Leonard H Calabrese; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

Review 4.  Role of PD-1 in HIV pathogenesis and as target for therapy.

Authors:  Filippos Porichis; Daniel E Kaufmann
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

5.  CD4+ T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures.

Authors:  Lillian Seu; James A Mobley; Paul A Goepfert
Journal:  Clin Immunol       Date:  2017-05-25       Impact factor: 3.969

6.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

Review 7.  Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy.

Authors:  Sarah M Kranick; Avindra Nath
Journal:  Continuum (Minneap Minn)       Date:  2012-12

8.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

9.  Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease.

Authors:  Leslie R Cockerham; Vivek Jain; Elizabeth Sinclair; David V Glidden; Wendy Hartogenesis; Hiroyu Hatano; Peter W Hunt; Jeffrey N Martin; Christopher D Pilcher; Rafick Sekaly; Joseph M McCune; Frederick M Hecht; Steven G Deeks
Journal:  AIDS       Date:  2014-07-31       Impact factor: 4.177

10.  Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection.

Authors:  Gaëlle Breton; Nicolas Chomont; Hiroshi Takata; Rémi Fromentin; Jeffrey Ahlers; Abdelali Filali-Mouhim; Catherine Riou; Mohamed-Rachid Boulassel; Jean-Pierre Routy; Bader Yassine-Diab; Rafick-Pierre Sékaly
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.